IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 92.16

Change

-0.32 (-0.35)%

Market Cap

N/A

Volume

0.15M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.39 (-0.26%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-0.27 (-0.38%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-0.07 (-0.06%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.55 (-1.68%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.24 (-0.97%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-0.53 (-1.31%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-1.07 (-1.10%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.09 (-0.29%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-1.84%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

-1.77 (-1.25%)

USD 1.43B
XHC:CA iShares Global Healthcare.. 99.90 % 0.65 %

-0.25 (-1.25%)

CAD 0.60B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.27% 14% F 48% F
Dividend Return 0.77% 63% D 11% F
Total Return 7.05% 19% F 39% F
Trailing 12 Months  
Capital Gain 12.93% 10% F 50% F
Dividend Return 1.50% 72% C 20% F
Total Return 14.43% 10% F 44% F
Trailing 5 Years  
Capital Gain 40.30% 57% F 66% D+
Dividend Return 8.11% 78% C+ 22% F
Total Return 48.41% 67% D+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.10% 57% F 56% F
Dividend Return 7.04% 62% D 52% F
Total Return 0.94% 74% C 22% F
Risk Return Profile  
Volatility (Standard Deviation) 13.03% 81% B- 72% C
Risk Adjusted Return 54.02% 81% B- 71% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike